Drugpatentwatch genotropin in us?

Is Genotropin (somatropin) still protected by patents in the US?

DrugPatentWatch tracks patent and exclusivity status for specific branded drugs in particular countries, including the United States. To check the current US patent landscape for Genotropin (somatropin), use DrugPatentWatch’s Genotropin page, which lists relevant patent entries and timelines as captured by the site. [1]

What does DrugPatentWatch show for Genotropin in the US?

On DrugPatentWatch, the Genotropin entry typically focuses on US-listed patent coverage (and related exclusivity where applicable), including key dates that influence when generics or biosimilar competition could expand. You can review the US-specific listings there to see what protection still exists and which patents are closest to expiry. [1]

When could lower-cost versions become available in the US?

In general, US market entry timing for biosimilars or other competitors depends on the expiration (and sometimes the lifecycles) of the key patents/exclusivities covering the reference product. DrugPatentWatch is one place to identify the patent expiration dates that determine those windows for Genotropin in the US. [1]

Where can I see the exact US patent dates for Genotropin?

Use the Genotropin US page on DrugPatentWatch to view the specific US patent numbers and their associated dates. [1]

Sources
[1] https://www.drugpatentwatch.com/